Loading organizations...
§ Private Profile · Jerusalem, Yerushalayim, Israel
Biopharmaceutical company developing advanced cell therapies for patients with blood cancers, focused on stem cell transplantation.
Based in Jerusalem, Israel, Gamida Cell is a biopharmaceutical company that develops advanced cell therapies using proprietary nicotinamide technology to expand umbilical cord blood stem cells for hematopoietic stem cell transplantation. The organization's lead product, omidubartseell, targets blood cancers such as leukemia and lymphoma, aiming to provide curative treatment options for patients who lack suitable bone marrow donors. Gamida Cell has secured significant capital to advance its clinical pipeline toward FDA approval, including a $40 million funding round and a $3.5 million Israeli government grant in 2019 to support manufacturing expansion. The biotechnology firm operates with a workforce of approximately 40 employees and has received financial backing and strategic support from notable industry entities like Novartis, Teva Pharmaceuticals, and Peregrine Ventures. Gamida Cell was founded in 1998 by Dr. Tony Peled and Rory Nealon.
Gamida Cell has raised $124.4M across 6 funding rounds.
Gamida Cell has raised $124.4M in total across 6 funding rounds.
Gamida Cell has raised $124.4M in total across 6 funding rounds.
Gamida Cell's investors include Highbridge Capital Management.
Gamida Cell has raised $124.4M across 6 funding rounds. Most recently, it raised $30.0M Other Equity in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 18, 2024 | $30M Venture Round | Highbridge Capital Management | — | Announced |
| Jun 19, 2017 | $40M Venture Round | — | — | Announced |
| May 23, 2016 | $4.4M Grant | — | — | Announced |
| Oct 12, 2015 | $5M Venture Round | — | — | Announced |
| Aug 22, 2014 | $35M Venture Round | — | — | Announced |
| May 15, 2012 | $10M Series E | — | — | Announced |